Clinical Trial

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Name: Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma — clinical trial record (NCT07480850)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

In patients with relapsed or refractory diffuse DLBCL who have not achieved complete remission in the mid-term, the treatment with Glofit+GemOx regimen is used.

Trial Details

NCT Number	NCT07480850
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions	Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment	40 participants
Start Date	2026-01-01
Primary Completion	2028-01-01 (estimated)
Study Completion	2028-01-02 (estimated)
Updated on ClinicalTrials.gov	2026-03-18